ClinicalTrials.gg
CompletedNCT05110157Updated Feb 10, 2026

Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

A Phase 3 interventional study of Placebo and Valbenazine in Schizophrenia, sponsored by Neurocrine Biosciences. Completed at 87 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Feb 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
442
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.

Enrollment
3rd of 16
442 · median 165
Started
2021
with 1 other
Phase 3
6 of 16
4 open now
Registered
6th of 16
by date

Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 3rd largest by enrollment, is one of 2 that started in 2021, is one of 6 in phase 3, and was the 6th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Schizophrenia by Neurocrine Biosciences, or all of them as a file.
02

Study summary

The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.

Read the detailed description

Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine when administered orally once daily as adjunctive treatment in participants with schizophrenia who have had an inadequate response to antipsychotics. The study will enroll approximately 400 participants with a diagnosis of schizophrenia. The expected duration of study participation for each participant is approximately 16 weeks.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Valbenazine
  • Antipsychotic
  • VMAT2
  • NBI-98854
  • Dopamine
  • Journey
  • Neurocrine
  • PANSS
  • Adjunctive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet all of the following inclusion criteria:
  1. Completed written .
  2. At the time of signing the informed consent, participant must be ≥18 years of age
  3. Medically confirmed diagnosis of schizophrenia as defined by the (DSM-5).
  4. The initial diagnosis of schizophrenia must be ≥1 year before the screening visit.
  5. Plasma levels for at least 1 of the participant's antipsychotic medications must be detectable by an available assay.
  6. The participant is treated with a stable regimen antipsychotic medication.
  7. Must meet all of the following criteria at the screening visit and Day 1:

    • PANSS total score ≥70
    • PANSS score of ≥4 on at least 1 of the following:

      • P1 (delusions)
      • P3 (hallucinations)
      • P6 (suspiciousness)
      • G9 (unusual thought content)
    • CGI-S score ≥4
    • Stable background antipsychotic medication dose between the screening visit and Day 1
    • Stable PANSS total score between the screening visit and Day 1
  8. The participant is outpatient with stable symptomatology
  9. The participant must have an adult informant (for example, a family member, relative, partner, social worker, caseworker, residential facility staff, or nurse).
  10. Female participants of must agree to use consistently from the screening visit until 30 days after the last dose of study drug or final study visit, whichever is longer.
  11. Male participants must agree to use contraception consistently from screening until 30 days after last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Participants will be excluded from the study if they meet any of the following criteria:

    1. Pregnant or breastfeeding or plans to become pregnant during the study. This criterion must be reconfirmed prior to the first dose of study treatment on Day 1.
    2. Known to any component of the formulation of valbenazine.
    3. Has history of treatment resistant schizophrenia.
    4. Evidence of depression as measured by a Calgary Depression Scale for Schizophrenia (CDSS) score ≥11 at the screening visit or Day 1.
    5. Participants with any suicidal behavior or suicidal ideation within 6 months before the screening visit or Day 1.
    6. Diagnosis of moderate or severe substance use disorder within the 6 months before the screening visit.
    7. Have a unstable medical condition within 60 days before the screening visit in the judgement of the investigator or any laboratory value outside the normal range that is considered by the investigator to be clinically significant at the screening visit.
    8. Prior (within 6 months of the screening visit) or concomitant use of any VMAT2 inhibitor.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
442 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo once daily.

    Drug: Placebo

  • Experimental
    Vesicular monoamine transporter 2 (VMAT2) inhibitor

    Valbenazine once daily

    Drug: Valbenazine

Interventions

  • DrugPlacebo

    Oral capsules

  • Oral capsules

    Also known as: NBI-98854

06

What researchers measure

Primary outcomes

  1. Change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to Week 10

    Time frame: Baseline to week 10

Secondary outcomes

  1. Change in Clinical Global Impression of Severity (CGI-S) score from baseline to Week 10

    Time frame: Baseline to week 10

  2. Change in Personal and Social Performance Scale (PSP) score from baseline to Week 10

    Time frame: Baseline to week 10

07

Study locations

87 sites
  • Neurocrine Clinical Site
    Phoenix, Arizona 85012, United States
  • Neurocrine Clinical Site
    Rogers, Arkansas 72758, United States
  • Neurocrine Clinical Site
    Anaheim, California 92805, United States
  • Neurocrine Clinical Site
    Bellflower, California 90706, United States
  • Neurocrine Clinical Site
    Culver City, California 90230, United States
  • Neurocrine Clinical Site
    Garden Grove, California 92845, United States
  • Neurocrine Clinical Site
    Lemon Grove, California 91945, United States
  • Neurocrine Clinical Site
    Long Beach, California 90807, United States
  • Neurocrine Clinical Site
    Oceanside, California 92056, United States
  • Neurocrine Clinical Site
    Pico Rivera, California 90660, United States
  • Neurocrine Clinical Site
    Riverside, California 92506, United States
  • Neurocrine Clinical Site
    San Diego, California 92102, United States
  • Neurocrine Clinical Site
    San Diego, California 92103, United States
  • Neurocrine Clinical Site
    San Jose, California 95124, United States
  • Neurocrine Clinical Site
    Santa Ana, California 92705, United States
  • Neurocrine Clinical Site
    Stanford, California 94305, United States
  • Neurocrine Clinical Site
    Torrance, California 90502, United States
  • Neurocrine Clinical Site
    Aventura, Florida 33180, United States
  • Neurocrine Clinical Site
    Coral Gables, Florida 33134, United States
  • Neurocrine Clinical Site
    Daytona Beach, Florida 32114, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33012, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33013, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33016, United States
  • Neurocrine Clinical Site
    Miami, Florida 33133, United States
  • Neurocrine Clinical Site
    Miami, Florida 33137, United States
  • Neurocrine Clinical Site
    Miami, Florida 33144, United States
  • Neurocrine Clinical Site
    Miami Lakes, Florida 33016, United States
  • Neurocrine Clinical Site
    Okeechobee, Florida 34972, United States
  • Neurocrine Clinical Site
    Tampa, Florida 33629, United States
  • Neurocrine Clinical Site
    West Palm Beach, Florida 33407, United States
  • Neurocrine Clinical Site
    Atlanta, Georgia 30328, United States
  • Neurocrine Clinical Site
    Evanston, Illinois 60208, United States
  • Neurocrine Clinical Site
    Springfield, Illinois 62702, United States
  • Neurocrine Clinical Site
    Grand Rapids, Michigan 49503, United States
  • Neurocrine Clinical Site
    St Louis, Missouri 63125, United States
  • Neurocrine Clinical Site
    St Louis, Missouri 63128, United States
  • Neurocrine Clinical Site
    Lincoln, Nebraska 68526, United States
  • Neurocrine Clinical Site
    Las Vegas, Nevada 89102, United States
  • Neurocrine Clinical Site
    Cedarhurst, New York 11516, United States
  • Neurocrine Clinical Sites
    Glen Oaks, New York 11004, United States
  • Neurocrine Clinical Site
    New York, New York 10032, United States
  • Neurocrine Clinical Site
    New York, New York 10035, United States
  • Neurocrine Clinical Site
    Charlotte, North Carolina 28211, United States
  • Neurocrine Clinical Site
    Dayton, Ohio 45417, United States
  • Neurocrine Clinical Site
    Oklahoma City, Oklahoma 73112, United States
  • Neurocrine Clinical Site
    Austin, Texas 78754, United States
  • Neurocrine Clinical Site
    Dallas, Texas 75390, United States
  • Neurocrine Clinical Site
    DeSoto, Texas 75115, United States
  • Neurocrine Clinical Site
    Houston, Texas 77081, United States
  • Neurocrine Clinical Site
    Houston, Texas 77090, United States
  • Neurocrine Clinical Site
    Buenos Aires, 1133, Argentina
  • Neurocrine Clinical Site
    Córdoba, 5004, Argentina
  • Neurocrine Clinical Site
    Kardzhali, 6600, Bulgaria
  • Neurocrine Clinical Site
    Lovech, 5500, Bulgaria
  • Neurocrine Clinical Site 1
    Pleven, 5800, Bulgaria
  • Neurocrine Clinical Site 2
    Pleven, 5800, Bulgaria
  • Neurocrine Clinical Site 1
    Plovdiv, 4000, Bulgaria
  • Neurocrine Clinical Site 2
    Plovdiv, 4000, Bulgaria
  • Neurocrine Clinical Site
    Plovdiv, 4002, Bulgaria
  • Neurocrine Clinical Site
    Plovdiv, 4004, Bulgaria
  • Neurocrine Clinical Site
    Rousse, 7003, Bulgaria
  • Neurocrine Clinical Site 1
    Sofia, 1000, Bulgaria
  • Neurocrine Clinical Site 2
    Sofia, 1000, Bulgaria
  • Neurocrine Clinical Site
    Sofia, 1113, Bulgaria
  • Neurocrine Clinical Site
    Sofia, 1408, Bulgaria
  • Neurocrine Clinical Site
    Sofia, 1510, Bulgaria
  • Neurocrine Clinical Site
    Sofia, 1680, Bulgaria
  • Neurocrine Clinical Site
    Veliko Tarnovo, 5000, Bulgaria
  • Neurocrine Clinical Site
    Vratsa, 3000, Bulgaria
  • Neurocrine Clinical Site 1
    Belgrade, 11000, Serbia
  • Neurocrine Clinical Site 2
    Belgrade, 11000, Serbia
  • Neurocrine Clinical Site 3
    Belgrade, 11000, Serbia
  • Neurocrine Clinical Site 4
    Belgrade, 11000, Serbia
  • Neurocrine Clinical Site 5
    Belgrade, 11000, Serbia
  • Neurocrine Clinical Site 6
    Belgrade, 11000, Serbia
  • Neurocrine Clinical Site
    Belgrade, 11108, Serbia
  • Neurocrine Clinical Site
    Gornja Toponica, 18202, Serbia
  • Neurocrine Clinical Site 1
    Kovin, 26220, Serbia
  • Neurocrine Clinical Site 2
    Kovin, 26220, Serbia
  • Neurocrine Clinical Site 1
    Kragujevac, 34000, Serbia
  • Neurocrine Clinical Site 2
    Kragujevac, 34000, Serbia
  • Neurocrine Clinical Site 3
    Kragujevac, 34000, Serbia
  • Neurocrine Clinical Site
    Niš, 18000, Serbia
  • Neurocrine Clinical Site
    Niš, 34000, Serbia
  • Neurocrine Clinical Site
    Novi Kneževac, 23330, Serbia
  • Neurocrine Clinical Site
    Vojvodina, 26300, Serbia
  • Neurocrine Clinical Site
    Vršac, 26300, Serbia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Feb 2025, 38 months.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 38 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2021
First posted
Nov 5, 2021
StartActual
Nov 29, 2021
Primary completionActual
Feb 4, 2025
CompletionActual
Feb 18, 2025
Results delay requested
Feb 2, 2026
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05110157
Responsible party
Sponsor
First posted
Nov 5, 2021
Start date
Nov 29, 2021
Primary completion
Feb 4, 2025
Completion
Feb 18, 2025
Last update
Feb 10, 2026

Study contacts

Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion